CagriSema FDA approval: when it's due, the dose filed, and what the trials showed
Reviewed 17 sourcesPublished by PepVault
CagriSema is not FDA approved yet (Nov 20, 2026); Novo expects a decision in Q4 2026. The dose it filed, the warnings to expect and five trials' numbers.

- Last reviewed
- Sources
- 17
- Questions
- 7
- Compounds
- 3
The short answer
Not yet. As of November 20, 2026, the FDA has not approved CagriSema, Novo Nordisk's weekly shot of cagrilintide 2.4 mg plus semaglutide 2.4 mg. Novo filed it on December 18, 2025, and expects a US decision in the fourth quarter of 2026 and a launch in early 2027. In its main trial, weight fell 20.4% at 68 weeks, against 3.0% on placebo.
Evidence: Strong for weight loss: five randomized phase 3 trials (REDEFINE 1, 2, 4, 5 and 9), two of them in the New England Journal of Medicine, all funded by Novo Nordisk. The approval itself is pending: decision and launch dates are Novo's expectations, not FDA statements.

Is CagriSema FDA approved yet?
No. On November 20, 2026, the FDA's drug database lists no approved product containing cagrilintide13, and neither the FDA nor Novo Nordisk has announced a decision. This page is updated the day one is.
What is on the table: Novo submitted a new drug application (NDA, the file a company sends the FDA to ask for approval) on December 18, 2025 for once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg, for adults with obesity, or overweight with at least one weight-related condition, beside a reduced-calorie diet and more activity1. The file rests on REDEFINE 1 and REDEFINE 21. In its nine-month report on November 4, 2026, Novo said it is "preparing for the US launch of CagriSema in early 2027, subject to regulatory approval"2, and its milestone table puts the US decision in the fourth quarter of 202623.
Why it matters: it would be the first approved shot to pair GLP-1 with amylin. Cagrilintide is an amylin analogue, a long-acting copy of the fullness hormone the pancreas releases with insulin, and semaglutide is the GLP-1 drug in Wegovy and Ozempic. The two curb appetite through partly different routes in the brain, and in REDEFINE 1 the pair lost more weight than either drug alone5.

When will the FDA decide on CagriSema?
Novo's word is the fourth quarter of 202623. Neither Novo nor the FDA has published the exact goal date, so the date below is our arithmetic from the FDA's own rules, not an announcement.
Cagrilintide has never been approved, so we expect the FDA to review CagriSema as a new molecular entity. Under the FDA's user-fee goals, a standard review of a new molecular entity aims to end with a decision within 10 months of the 60-day filing date, about 12 months after the file arrives12. For a December 18, 2025 submission, the filing date is February 16, 2026, and ten months on is about December 16, 2026. If Novo sends a major amendment during the review, such as a big new analysis, the FDA may push the date back by three months, once per review12. The decision can be an approval or a complete response letter, the FDA's list of what must be fixed first.
| Date | What happened or is expected | Whose date |
|---|---|---|
| Dec 20, 2024 | REDEFINE 1 headline results5 | Fixed (Novo announcement) |
| Jun 22, 2025 | REDEFINE 1 and 2 published in NEJM67 | Fixed |
| Dec 18, 2025 | NDA submitted to the FDA1 | Fixed (Novo announcement) |
| Feb 23, 2026 | REDEFINE 4 head to head with tirzepatide reported4 | Fixed (Novo announcement) |
| Nov 14, 2026 | REDEFINE 9, the lower doses, published9 | Fixed |
| Q4 2026 | US decision23 | Novo's expectation |
| Early 2027 | US launch, if approved2 | Novo's expectation |
| Mar 1, 2027 | REDEFINE 11 primary completion10 | Registry estimate, ClinicalTrials.gov |
What dose did Novo file, and what dose steps did the trials use?
The application names one maintenance dose: 2.4 mg of cagrilintide plus 2.4 mg of semaglutide, once a week1. CagriSema doses are written per drug, so 2.4 mg/2.4 mg means 2.4 mg of each. No label exists yet, so the steps below are the trials', not an approved schedule.
| Trial step | Dose of each drug | Source |
|---|---|---|
| Start | 0.25 mg once a week | REDEFINE 99 |
| Step-ups | Every 4 weeks | REDEFINE 11 record10 |
| After 8 weeks | 1.0 mg reached (the lowest maintenance dose tested) | REDEFINE 99 |
| After 12 weeks | 1.7 mg reached | REDEFINE 99 |
| After 16 weeks | 2.4 mg reached, the filed maintenance dose | REDEFINE 1 record11 |
REDEFINE 1 let people adjust their dose along the way. At week 68, 57.3% of people on CagriSema were on the top dose, against 70.2% on semaglutide alone and 82.5% on cagrilintide alone5. Novo followed with two trials: REDEFINE 9, which tested lower maintenance doses, and REDEFINE 11, which tests 2.4 mg/2.4 mg in people who aim to lose a quarter of their weight.
REDEFINE 9 is the newest result. Counting people as if they stayed on treatment, weight fell 21.0% on 1.0 mg of each and 20.7% on 1.7 mg of each, against 2.0% on placebo9. Whether a first label includes those lower doses is one of the things to read on decision day: the application as announced named 2.4 mg/2.4 mg1. Which dose a person takes, and when they step up, is the prescriber's decision.
Once CagriSema is prescribed, PepVault can remind you on your shot day, log each weekly dose as you took it, and keep your weight beside it, so each step-up is easy to review with your prescriber. Set reminders in PepVault
What did the CagriSema trials show?
Five phase 3 obesity trials have reported, all funded by Novo. Two ways of counting appear below. The treatment-policy number counts everyone who started, including those who stopped the drug; the efficacy number estimates what happens if everyone stays on treatment, and runs higher.
| Trial | Who and how long | Weight change | Stopped for side effects |
|---|---|---|---|
| REDEFINE 156 | 3,417 adults without diabetes, 68 weeks | −20.4% vs −3.0% placebo, semaglutide alone −14.9%, cagrilintide alone −11.5% (treatment policy); −22.7% vs −2.3% placebo (efficacy) | 5.9% vs 3.5% on placebo1 |
| REDEFINE 27 | 1,206 adults with type 2 diabetes, 68 weeks | −13.7% vs −3.4% placebo (treatment policy) | 8.4% vs 3% on placebo1 |
| REDEFINE 58 | 331 adults in Japan and Taiwan, with or without type 2 diabetes, 68 weeks | −18.4% vs −11.9% on semaglutide 2.4 mg (efficacy) | 10% stopped CagriSema, 6% semaglutide (any reason) |
| REDEFINE 99 | 309 adults without diabetes, 68 weeks, lower doses | −21.0% (1.0 mg each), −20.7% (1.7 mg each) vs −2.0% placebo (efficacy) | Not in the abstract; 82% still on treatment at week 68 |
| REDEFINE 4417 | 809 adults with obesity, 84 weeks, open label, vs tirzepatide 15 mg | −23.0% vs −25.5% (efficacy); −20.2% vs −23.6% (treatment regimen) | Not reported in the announcement |
Two results frame the decision. Against placebo and against semaglutide alone, CagriSema won clearly: in REDEFINE 1, 40.4% of people lost a quarter or more of their body weight if they stayed on treatment, against 16.2% on semaglutide alone5. Against tirzepatide 15 mg, the Zepbound top dose, it did not reach its goal of proving it no worse4. The application rests on the placebo-controlled REDEFINE 1 and 21, so a missed head-to-head goal does not by itself decide the review. How CagriSema, Zepbound and Wegovy compare is its own guide.
What side effects and warnings will the label likely carry?
Mostly stomach and gut effects, like every GLP-1 drug. In REDEFINE 1, 79.6% on CagriSema had a gut side effect at some point, against 39.9% on placebo, mostly passing and mild to moderate6: nausea in 55%, constipation in 30.7% and vomiting in 26.1%1. In REDEFINE 2 the gut rate was 72.5% against 34.4%7, and in REDEFINE 5, against semaglutide alone, it was 53% against 51%8.
The label's exact wording is the FDA's to write. CagriSema contains semaglutide, so Wegovy's label is the closest guide. It has a boxed warning, the FDA's strongest, because semaglutide caused thyroid C-cell tumors in rodents; whether it does in people is unknown, and the drug is ruled out for anyone with a personal or family history of medullary thyroid cancer or MEN 214. Its other warnings cover pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, severe stomach effects, allergic reactions, diabetic eye complications, a faster heart rate, and the risk of inhaling stomach contents under anesthesia14. Our expectation is that a CagriSema label opens with the same boxed warning; whether amylin adds anything new is what the label will show.
Commonly reported: strong appetite loss and fullness arriving early in a meal, with nausea, vomiting or constipation in the days after each step-up, settling once the dose holds steady.
When to get help Severe stomach pain that does not ease, sometimes reaching the back, is the semaglutide label's sign to stop and call a doctor14.
What is REDEFINE 11, and when does it report?
REDEFINE 11 is Novo's answer to the dose question REDEFINE 1 left open: the trial "exploring CagriSema 2.4/2.4 mg full weight-loss potential", expected to report in the first half of 202742. The registry record that matches Novo's description, NCT07011667, enrolled 609 adults with a BMI of 30 or more and no diabetes at 47 US sites, every one of whom said they wished to lose at least 25% of their weight10. They take CagriSema or placebo, stepped up every 4 weeks over 16 weeks, then held for 64 more; the primary endpoint, the result the trial is built to test, is the change in body weight at 80 weeks10. Primary completion, per ClinicalTrials.gov, is March 1, 2027, an estimate and not a results date10.
REDEFINE 11 comes after the decision, so it cannot shape the first label. It could shape the second. The number to compare it with is REDEFINE 1's: 22.7% at 68 weeks for people who stayed on treatment5. Two larger trials follow it: REDEFINE 3, a heart outcomes trial in 7,101 people with cardiovascular disease, primary completion September 2027 per ClinicalTrials.gov15, with results Novo expects in the second half of 20272, and a high-dose trial of cagrilintide 2.4 mg with semaglutide 7.2 mg, which Novo expects to read out in the first half of 2028316.
What should you look for on decision day?
On decision day, the press release and the label answer these, in order:
- Approved or not: an approval, or a complete response letter with what is missing.
- The brand name: CagriSema is a working name, and the brand appears with the approval.
- Who it is for: the filing asked for adults with obesity, or overweight with a weight-related condition1.
- The maintenance dose or doses: 2.4 mg/2.4 mg only, or also the 1.0 and 1.7 mg steps REDEFINE 9 tested.
- The dose schedule: how many weeks each step lasts and how the pen is used.
- The boxed warning and any amylin-specific warning.
- The list price, and when pharmacies stock it: Novo expects the US launch in early 20272.
PepVault logs CagriSema as one weekly shot, so the dose you took and the weight trend that follows sit on one screen for your prescriber. Log it in PepVault
Sources
- Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema (company announcement). December 18, 2025. novonordisk.com
- Novo Nordisk A/S, Form 6-K: Financial report for 1 January to 30 September 2026 (company announcement No 65/2026). November 4, 2026. sec.gov
- Novo Nordisk A/S, Form 6-K: Financial report for the first six months of 2026 (R&D update and anticipated milestones). sec.gov
- Novo Nordisk. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial (company announcement). February 23, 2026. novonordisk.com
- Novo Nordisk A/S, Form 6-K: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial (company announcement No 99/2024). December 20, 2024. sec.gov
- Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025. PubMed 40544433
- Davies MJ et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med. 2025. PubMed 40544432
- Yamauchi et al. Co-administered cagrilintide and semaglutide versus semaglutide alone in Japan and Taiwan (REDEFINE 5). Lancet Diabetes Endocrinol. 2026. PubMed 42009015
- Wharton S et al. Cagrilintide-semaglutide 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9). Lancet Diabetes Endocrinol. 2026. PubMed 43033821
- ClinicalTrials.gov NCT07011667: CagriSema for weight management and long-term weight maintenance in participants with obesity (Novo Nordisk; REDEFINE 11). clinicaltrials.gov
- ClinicalTrials.gov NCT05567796: REDEFINE 1 (Novo Nordisk). clinicaltrials.gov
- FDA. PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027 (PDUFA VII commitment letter), section I.A. fda.gov
- openFDA Drugs@FDA: search for products with the active ingredient cagrilintide (no matches, November 20, 2026). api.fda.gov
- WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed, June 2026. dailymed.nlm.nih.gov
- ClinicalTrials.gov NCT05669755: REDEFINE 3, CagriSema cardiovascular outcomes (Novo Nordisk). clinicaltrials.gov
- ClinicalTrials.gov NCT07564414: two doses of CagriSema and semaglutide in obesity with or without type 2 diabetes (Novo Nordisk). clinicaltrials.gov
- ClinicalTrials.gov NCT06131437: REDEFINE 4, CagriSema 2.4 mg/2.4 mg vs tirzepatide 15 mg (Novo Nordisk). clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.